Amylyx Pharmaceuticals Added to S&P Pharmaceuticals Select Industry Index

Amylyx Pharmaceuticals has been added to the S&P Pharmaceuticals Select Industry Index. The company is a commercial-stage biopharmaceutical firm focused on developing treatments for neurodegenerative diseases, including AMX0035 for Wolfram syndrome and progressive supranuclear palsy, and AMX0114 for amyotrophic lateral sclerosis. Amylyx also has Avexitide, an investigational GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism.